EGFR and cancer: NIR-PIT targeting EGFR-expressing cancer cells has been approved for clinical use in Japan (Rakuten Medical Inc.)and is currently in Phase 3 clinical trials in the United States (ClinicalTrials.gov Identifier: NCT02422979) [38], indicating a promising level of safety and efficacy in humans.